Stocks making the biggest moves after hours: Zscaler, Insulet, Box and more

After-hours moves were driven by a mixed batch of earnings and guidance updates: Box fell 2% after full-year adjusted EPS guidance of $1.56 missed the $1.63 consensus, while Zscaler tumbled 16% on current-quarter revenue guidance of $875 million-$878 million versus $879 million expected despite a Q3 beat. Semtech rose 8% on better-than-expected results and stronger guidance, Modine gained 1% after topping estimates, and Insulet dropped about 9% on a voluntary pod correction tied to potential insulin under-delivery.

Analysis

The cleanest read is that guidance risk is now driving the tape more than reported-quarter beats, and that matters because it shifts capital from “execution stories” to “forward visibility” names. In cyber, the dispersion is likely to widen: Zscaler’s miss on near-term revenue growth raises the bar for multiple expansion across the category, but it also creates a relative opportunity for the more platform-oriented incumbents if budget scrutiny pushes customers to consolidate vendors rather than add point solutions. The sympathy move in PANW/CRWD looks mechanical and probably over-extends if their next few prints remain stable.

Semtech is the opposite setup: a strong guide into data-center-related demand can re-rate the stock beyond a single quarter because it validates that AI infrastructure spend is leaking into adjacent component suppliers, not just the hyperscalers. That second-order effect is important for the supply chain—if cooling, power, and connectivity bottlenecks persist, this broadens the beneficiary set and supports further upside in niche semiconductor and thermal-management names over the next 1-2 quarters. Modine’s print reinforces that the market is willing to pay up for AI-enabler exposure when orders convert into visible backlog.

Insulet is a different kind of event: a product correction is a trust shock, not just a margin headwind. The near-term downside can persist for weeks as clinicians and patients digest whether this is isolated or a signal of broader manufacturing quality drift; the larger risk is slower new-patient starts and higher scrutiny from payers/distributors over the next 1-3 quarters. Box remains a lower-conviction name because the miss is small but the guide confirms that efficiency gains are being priced in already, so upside likely depends on a reacceleration narrative rather than cost control alone.

Key Decisions for Investors

• Short ZS on any post-earnings bounce; use a 1-3 week horizon. Risk/reward favors continuation lower if the market starts de-rating near-term growth across cybersecurity, with a tight stop above the pre-gap level.
• Long SMTC vs short ZS as a pair trade for 1-2 months. The thesis is that AI-infrastructure adjacency is getting rewarded while near-term guide disappointments in software security get punished; target further multiple divergence if enterprise spend stays selective.
• Buy PANW and/or CRWD only on further weakness, not chase strength; 2-6 week horizon. The sympathy selloff likely overstates company-specific damage, so this is a better relative-value long than an outright momentum short.
• Avoid catching PODD too early; consider put spreads or a short-term short only if management signals broader quality issues. The correction risk can create a multi-week overhang, but upside reversal would require clear evidence the issue is contained.
• Add MOD on pullbacks over the next several sessions. The setup is a good industrial AI-enablement barbell: backlog visibility can support another leg higher, but risk/reward is best after the first reaction fades.